VMI
ADVM

VHCP Management III’s Adverum Biotechnologies ADVM Stock Holding History

VHCP Management III’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$10.9M Buy
+94,623
New +$8.34M 2.16% 11

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
KL
Kam Lawrence $97.4M AUM
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VHCP Management III's ADVM Position: Q4 2019 in Review

VHCP Management III opened a new position in Adverum Biotechnologies (ADVM) in Q4 2019: 94,623 shares worth $10.9M. The stake represents 2.16% of the portfolio and ranks #11 among its holdings.

116 funds tracked by Wall St. Rank hold ADVM as of Q4 2019.

  • VHCP Management III held 94,623 shares of Adverum Biotechnologies worth $10.9M as of Q4 2019.
  • Adverum Biotechnologies was a new VHCP Management III position in Q4 2019.
  • Adverum Biotechnologies made up 2.16% of VHCP Management III's portfolio in Q4 2019, its #11 holding.
  • 116 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2019.

Based on VHCP Management III's 13F filing for Q4 2019, filed 13 Feb 2020.